Calmark modifies its communication policy relating to sales and orders

To enhance transparency in respect of the launching and sales of Calmark’s products, the Company announces a modification of the communication policy. 

Henceforth, the following policy on sales will apply: 

• The first order from a new country, or, in cases where a country is addressed by multiple distributors, a new distributor.
• Orders considered significant for the company, irrespective of the order value.

Calmark will continue to comply with the disclosure requirements imposed on the company by the agreement with Spotlight Stock Market and other relevant applicable laws and regulations.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.